ESPR Q3 2022 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$19M+31.7% YoY

Gross Profit

$12M65.7% margin

Operating Income

-$42M-219.3% margin

Net Income

-$55M-290.4% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$313M

Total Liabilities

$607M

Stockholders' Equity

-$294M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$14M	+31.7%
Gross Profit	$12M	$9M	+40.9%
Operating Income	-$42M	-$56M	+25.3%
Net Income	-$55M	-$69M	+20.6%

Revenue Segments

Collaboration Revenue

$5M53%

Royalty Revenue And Product Sales Bulk Tablets

$4M47%